Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MYO-029 · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| MYO-029 | DRUG | - |
Inclusion Criteria: * Written informed consent. * Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD) * Independently ambulatory Exclusion Criteria: * Patients with certain clinical ...
MYO-029 was studied for the treatment of Becker Muscular Dystrophy, a rare inherited muscle-wasting condition. A Phase 1 trial also enrolled adults with facioscapulohumeral muscular dystrophy and limb-girdle muscular dystrophy. It is an investigational small molecule and is not an approved therapy for any indication.
MYO-029 was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical program evaluating the compound in adult muscular dystrophies, including Becker Muscular Dystrophy.
MYO-029 reached Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are ongoing. The program remains investigational and has not advanced beyond early-stage testing for Becker Muscular Dystrophy.
MYO-029 was evaluated in a single completed Phase 1 study, NCT00104078, titled Study Evaluating MYO-029 in Adult Muscular Dystrophy. The trial enrolled 108 adults aged 18 years and older in the United States and covered Becker, facioscapulohumeral, and limb-girdle muscular dystrophies.
NCT00104078 was a randomized, double-blind Phase 1 study of MYO-029 in 108 adults with muscular dystrophy, conducted at sites in the United States. It enrolled patients rather than healthy volunteers and did not use a placebo control group. The study is listed as completed.